NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $17,500,000 Common Stock Offering At-The-Market
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 each, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. There are no warrants in the offering. The company intends to use the proceeds from the offering, which are anticipated to be roughly $17,500,000 before deducting fees and other estimated offering expenses, towards the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement agent, and Joseph Gunnar & Co., LLC is acting as co-placement agent for the offering. Subject to the satisfaction of customary closing conditions, the registered direct offering is expected to close on or about February 21, 2020.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, on Wednesday announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 each, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. There are no warrants in the offering. The company intends to use the proceeds from the offering, which are anticipated to be roughly $17,500,000 before deducting fees and other estimated offering expenses, towards the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement agent, and Joseph Gunnar & Co., LLC is acting as co-placement agent for the offering. Subject to the satisfaction of customary closing conditions, the registered direct offering is expected to close on or about February 21, 2020.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
